Radcliffe Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Radcliffe Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40,680	Closed	-$4.04M	–	907
2021 Q2	$4.04M	Hold	40,680	–	–	0.13%	234
2021 Q1	$4.04M	Hold	40,680	–	–	0.16%	219
2020 Q4	$4.07M	Buy	40,680 +13,000	+47%	+$1.29M	0.26%	127
2020 Q3	$2.75M	Buy	27,680 +990	+4%	+$98.9K	0.25%	98
2020 Q2	$2.7M	Buy	26,690 +630	+2%	+$61.6K	0.37%	52
2020 Q1	$2.5M	Buy	+26,060	New	+$2.55M	0.46%	45

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Radcliffe Capital Management's JSPR Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 40,680 shares — an estimated $4.04M sold.

Radcliffe Capital Management first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $4.07M in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Radcliffe Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Radcliffe Capital Management sold 40,680 Jasper Therapeutics shares in Q3 2021, an estimated $4.04M.
Radcliffe Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
Radcliffe Capital Management's Jasper Therapeutics position peaked at $4.07M in Q4 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.